医疗专业人员

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to store blood, serum and bone marrow so that they can be used for laboratory studies that may contribute to finding the exact function of the CART cells or T-cell engager therapy such as bispecific and trispecific antibodies and the factors that may determine disease progression and treatment response.

2. Spinal Cord Stimulation to Treat Chemotherapy-Induced Peripheral Neuropathy

   Rochester, Minn.

   The purpose of this study is to understand pain outcomes in patients with cancer who have Chemotherapy-Induced Peripheral Neuropathy (CIPN).

3. IL-2 plus FOLFOX and Nivolumab for Treatment of Peritoneal Metastases

   Rochester, Minn.

   The purpose of this study is to evaluate the reduction in the peritoneal carcinomatosis index (PCI) after completion of the study treatment.

4. A Study to Assess Dynamic Changes in Plasma Proteome to Identify Early Detection and Treatment Response Biomarkers for HGSOC

   Rochester, Minn.

   This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers.  For the purpose of this study we define high grade serous cancers to include invasive cancers arising in the ovary and/or fallopian tubes (FT).  Using mass spectrometry we will deeply profile and quantitate dynamic changes in the plasma proteome and N-gylcocapture sub-proteome that occur as a consequence of surgical debulking and platinum-based chemotherapy.  

5. Adipose-Derived Mesenchymal Stem Cells (AMSCs) For Recurrent Glioblastoma

   Jacksonville, Fla.

   This study aims to evaluate the safety of local delivery of AMSCs for recurrent GBM by noting the incidence of adverse events, as well as radiological and clinical progression.

   To assess the preliminary efficacy of local delivery of AMSCs for recurrent GBM by comparing the clinical, survival, progression, and radiographic outcomes from patients enrolled in our study to historical controls from our institution.

6. Exploring Mechanisms of Action and Resistance of Therapeutic Agents in Patients with B-cell Malignancies

   Jacksonville, Fla.

   This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers. We aim to identify the reasons why certain therapies work and others don’t and as result- develop new treatments for blood cancers.

7. A Study to See if the Depth of Tumor Invasion of Esophageal Carcinoma Predicts Lymph Node Involvement and Cancer Free Survival

   Rochester, Minn.

   The purpose of this study is to see if different depths of submucosal tumor invasion in esophageal cancer can predict lymph node involvement and survival.

8. A Study of Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to collect vaginal and endometrial cell samples to study endometrial cancer.

9. A Study to Evaluate the Safety of the Goldilocks Procedure with Implant-Based Reconstruction

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess outcomes, satisfaction and aesthetics of two different breast reconstruction techniques (Goldilocks alone, and Goldilocks with Implant-Based Reconstruction) and compare its safety, patient satisfaction, aesthetic evaluation and complications.

10. Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

    Rochester, Minn.

    This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells.